Hostname: page-component-7479d7b7d-k7p5g Total loading time: 0 Render date: 2024-07-10T15:58:53.594Z Has data issue: false hasContentIssue false
  • English
  • Français

Update: New Uses for Lithium and Anticonvulsants

Published online by Cambridge University Press:  07 November 2014

Jennifer M. Rosenberg  and
Carl Salzman
Get access Rights & Permissions [Opens in a new window]

Abstract

Anticonvulsants are being used clinically as monotherapy and adjuncts in mental illnesses other than affective disorders. This review focuses on the literature for anticonvulsants and lithium in substance use disorders, anxiety disorders, and schizophrenia. Given the abuse potential and other difficulties with prescribing benzodiazepines for alcohol and benzodiazepine withdrawal, anticonvulsants have been considered as an alternative. Promising therapeutic effects have been demonstrated in many of the anxiety disorders, with the greatest number of trials and positive results in posttraumatic stress disorder. Although anticonvulsant and lithium augmentation for schizophrenia is common in practice and has been studied in double-blind, randomized, controlled trials, the sum of the evidence has been inconclusive.

Type
Review Articles
Information
CNS Spectrums , Volume 12 , Issue 11 , November 2007 , pp. 831 - 841
Copyright
Copyright © Cambridge University Press 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Salzman, C. New uses for lithium and anticonvulsants. Harv Rev Psychiatry. 2003;11:230–244.CrossRefGoogle ScholarPubMed
2.Raby, WN, Coomaraswamy, S. Gabapentin reduces cocaine use among addicts from a community clinic sample. J Clin Psychiatry. 2004;65:84–86.CrossRefGoogle ScholarPubMed
3.Andrews, N, Loomis, S, Blake, R, Ferrigan, L, Singh, L, McKnight, AT. Effect of gabapentin-like compounds on development and maintenance of morphine-induced conditioned place preference. Psychopharmacology (Berl). 2001;157:381–387.CrossRefGoogle ScholarPubMed
4.Martinez-Raga, J, Sabater, A, Perez-Galvez, B, Castellano, M, Cervera, G. Add-on gabapentin in the treatment of opiate withdrawal. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:599–601.CrossRefGoogle ScholarPubMed
5.Campbell, J, Nickel, EJ, Penick, EC, et al.Comparison of desipramine or carbamazepine to placebo for crack cocaine-dependent patients. Am J Addict. 2003;12:122–136.Google ScholarPubMed
6.Cornish, JW, Maany, I, Fudala, PJ, et al.Carbamazepine treatment for cocaine dependence. Drug Alcohol Depend. 1995;38:221–227.CrossRefGoogle ScholarPubMed
7.Kranzler, HR, Bauer, LO, Hersh, D, Klinghoffer, V. Carbamazepine treatment of cocaine dependence: a placebo-controlled trial. Drug Alcohol Depend. 1995;38:203–211.CrossRefGoogle ScholarPubMed
8.Montoya, ID, Levin, FR, Fudala, PJ, Gorelick, DA. Double-blind comparison of carbamazepine and placebo for treatment of cocaine dependence. Drug Alcohol Depend. 1995;38:213–219.CrossRefGoogle ScholarPubMed
9.Halikas, JA, Crosby, RD, Pearson, VL, Graves, NM. A randomized double-blind study of carbamazepine in the treatment of cocaine abuse. Clin Pharmacol Ther. 1997;62:89–105.CrossRefGoogle ScholarPubMed
10.Schweizer, E, Rickels, K, Case, WG, Greenblatt, DJ. Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Effects on withdrawal severity and outcome. Arch Gen Psychiatry. 1991;48:448–452.CrossRefGoogle ScholarPubMed
11.Klein, E, Uhde, TW, Post, RM. Preliminary evidence for the utility of carbamazepine in alprazolam withdrawal. Am J Psychiatry. 1986;143:235–236.Google ScholarPubMed
12.Ries, RK, Roy-Byrne, PPWard, NG, Neppe, V, Cullison, S. Carbamazepine treatment for benzodiazepine withdrawal. Am J Psychiatry. 1989;146:536–537.Google ScholarPubMed
13.Cheseaux, M, Monnat, M, Zullino, DF. Topiramate in benzodiazepine withdrawal. Hum Psychopharmacol. 2003;18:375–377.CrossRefGoogle ScholarPubMed
14.Haney, M, Hart, CL, Vosburg, SK, et al.Marijuana withdrawal in humans: effects of oral THC or Divalproex. Neuropsychopharmacology. 2004;29:158–170.CrossRefGoogle ScholarPubMed
15.Levin, FR, McDowell, D, Evans, SM, et al.Pharmacotherpy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium. Am J Addict. 2004;13:21–32.CrossRefGoogle Scholar
16.Johnson, BA, Ait-Daoud, N, Bowden, CL, et al.Oral topiramate for treatment of alcohol dependence: a randomized control trial. Lancet. 2003;361:1677–1685.CrossRefGoogle Scholar
17.Johnson, BA, Ait-Daoud, N, Akhtar, FZ, Ma, JZ. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals. Arch Gen Psychiatry. 2004;61:905–912.CrossRefGoogle ScholarPubMed
18.Komanduri, R. Two cases of alcohol craving curbed by topiramate. J Clin Psychiatry. 2003;65:612.CrossRefGoogle Scholar
19.Rubio, G, Ponce, G, Jimenez-Arriero, MA, Palomo, T, Manzanares, J, Ferre, F. Effects of topiramate in the treatment of alcohol dependence. Pharmacopsychiatry. 2004;37:37–40.Google ScholarPubMed
20.Reoux, JRSaxon, AJ, Malta, CA, Baer, JS, Sloan, KL. Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial. Alcohol Clin Exp Res. 2001;25:1324–1329.Google ScholarPubMed
21.Bastie, Y. Suppression des crises d'epilepsie du sevrage par le depakine dans les cures de desintoxication ethylique. Ann Med Psychol (Paris). 1970;2:400–404.Google Scholar
22.Brady, KT, Myrick, H, Henderson, S, Coffey, SF. The use of divalproex in alcohol relapse prevention: a pilot study. Drug Alcohol Depend. 2002;67:323–330.CrossRefGoogle ScholarPubMed
23.Longo, LP, Campbell, T, Hubatch, S. Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention. J Addict Dis. 2002;21:55–64.CrossRefGoogle ScholarPubMed
24.Salloum, IM, Cornelius, JR, Daley, DC, Kirisci, L, Himmelhoch, JM, Thase, ME. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism. Arch Gen Psychiatry. 2005;62:37–45.CrossRefGoogle ScholarPubMed
25.Malcolm, R, Myrick, H, Roberts, J, Wand, W, Anton, RF, Ballenger, JC. The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial. J Gen Intern Med. 2002;17:349–355.CrossRefGoogle Scholar
26.Ritola, E, Malinen, L. A double-blind comparison of carbamazepine and clomethiazole in the treatment of alcohol withdrawal syndrome. Acta Psychiatr Scand. 1981;64:254–259.CrossRefGoogle ScholarPubMed
27.Flygenring, J, Hansen, J, Hoist, B, Peterson, E, Sorensen, A. Treatment of alcohol withdrawal symptoms in hospitalized patients. A randomized, double-blind comparison of carbamazepine (Tegretol) and barbital (Diemal). Acta Psychiatr Scand. 1984;69:398–408.CrossRefGoogle ScholarPubMed
28.Stuppaeck, CH, Pycha, R, Miller, C, Whitworth, AB, Oberbauer, H, Fleischhaker, WW. Carbamazepine versus oxazepam in the treatment of alcohol withdrawal: a double-blind study. Alcohol Alcohol. 1992;27:153–158.Google ScholarPubMed
29.Stuppaeck, CH, Barnas, C, Hackenberg, K, Miller, CH, Fleishhacker, WW. Carbamazepine monotherapy in the treatment of alcohol withdrawal. Int Clin Psychopharmacol. 1990;5:273–278.CrossRefGoogle ScholarPubMed
30.Mueller, TI, Stout, RL, Rudden, S, et al.A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcohol Clin Exp Res. 1997;21:86–92.CrossRefGoogle ScholarPubMed
31.Bjorkqvist, SE, Isohanni, M, Makela, R, Malinen, L. Ambulant treatment of alcohol withdrawal symptoms with carbamazepine: a formal multicentre double-blind comparison with placebo. Acta Psychiatr Scand. 1976;53:333–342.CrossRefGoogle ScholarPubMed
32.Myrick, H, Malcolm, R, Brady, KT. Gabapentin treatment of alcohol withdrawal. Am J Psychiatry. 1998;155:1632.CrossRefGoogle ScholarPubMed
33.Bonnet, U, Banger, M, Lewele, FM, Maschke, M, Kowalski, T, Gastpar, M. Treatment of alcohol withdrawal syndrome with gabapentin. Pharmacopsychiatry. 1999;32:107–109.CrossRefGoogle ScholarPubMed
34.Bozikas, V, Petrikis, P, Gamvrula, K, Savvidou, I, Karavatos, A. Treatment of alcohol withdrawal with gabapentin. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:197–1199.CrossRefGoogle ScholarPubMed
35.Karam-Hage, Brower KJ. Gabapentin treatment for insomnia with alcohol dependence. Am J Psychiatry. 2000;157:2058–2059.CrossRefGoogle ScholarPubMed
36.Bonnet, U, Banger, M, Leweke, M, et al.Treatment of acute alcohol withdrawal with gabapentin: results from a controlled two-center trial. J Clin Psychopharmacol. 2003;23:514–519.CrossRefGoogle ScholarPubMed
37.Voris, J, Smith, NL, Rao, SM, Thorne, DL, Flowers, QJ. Gabapentin for the treatment of ethanol withdrawal. Subst Abus. 2003;24:129–132.CrossRefGoogle ScholarPubMed
38.Stahl, SM. Independent actions on fear circuits may lead to therapeutic synergy for anxiety when combining serotonergic and GABAergic agents. J Clin Psychiatry. 2002;63:854–855.CrossRefGoogle ScholarPubMed
39.Coplan, JD, Lydiard, RB. Brain circuits in panic disorder. Biol Psychiatry. 1998;44:1264–1276.CrossRefGoogle ScholarPubMed
40.Stutzmann, GE, LeDoux, JE. GABAergic antagonists block the inhibitory effects of serotonin in the lateral amygdala: a mechanism for modulation of sensory inputs related to fear conditioning. J Neurosci. 1999;19:RC8.CrossRefGoogle ScholarPubMed
41.Taylor, FB. Tiagabine for posttraumatic stress disorder: a case series of 7 women. J Clin Psychiatry. 2003;64:1421–1425.CrossRefGoogle ScholarPubMed
42.Stahl, SM. Essential Psychopharmacology of Depression and Bipolar Disorder. 2nd ed. New York, NY: Cambridge University Press; 2002.Google Scholar
43.Stahl, SM. Anticonvulsants and the relief of chronic pain: pregabalin and gabapentin as alpha(2)delta ligands at voltage-gated calcium channels. J Clin Psychiatry. 2004;65:460–461.CrossRefGoogle ScholarPubMed
44.Swann, AC. Neuroreceptor mechanisms of aggression and its treatment. J Clin Psychiatry. 2003;64(suppl 4):26–35.Google ScholarPubMed
45.Van der Kolk, BA. The psychobiology of PTSD. J Clin Psychiatry. 1997;58(suppl 9):16–24.Google Scholar
46.Clark, RD, Canive, JM, Calais, LA, Qvalis, CR, Tuason, VB. Divalproex in posttraumatic stress disorder: an open label clinical trial. J Trauma Stress. 1999;12:395–401.CrossRefGoogle ScholarPubMed
47.Frederick, P, Davis, L, Nugent, A, et al.Valproate therapy for chronic, combat-induced posttraumatic stress disorder. J Clin Psychopharmacol. 2002;22:100–101.Google Scholar
48.Fesler, FA. Valproate in combat-related posttraumatic stress disorder. J Clin Psychiatry. 1991;52:361–364.Google ScholarPubMed
49.Otte, C, Wiedemann, K, Yassouridis, A, Kellner, M. Valproate monotherapy in the treatment of civilian patients with non-combat-related posttraumatic stress disorder: an open-label study. J Clin Psychopharmacol. 2004;24:106–108.CrossRefGoogle ScholarPubMed
50.Berigan, TR, Holzgang, A. Valproate as an alternative in posttraumatic stress disorder: a case report. Mil Med. 1995;160:318CrossRefGoogle ScholarPubMed
51.Brodsky, L, Doerman, AL, Palmer, LS, Slade, GF, Munasifi, FA. Posttraumatic stress disorder: an eclectic approach. Int J Psychosom. 1990;37:89–95.Google ScholarPubMed
52.Szymanski, HV, Olympia, J. Divalproex in posttraumatic stress disorder. Am J Psychiatry. 1991;148:1086–1087.Google ScholarPubMed
53.Lipper, S, Davidson, JR, Grady, TA, et al.Preliminary study of carbamazepine in posttraumatic stress disorder. Psychosomatics. 1986;27:849–854.CrossRefGoogle Scholar
54.Viola, J, Ditzler, T, Batzer, W, et al.Pharmacological management of post-traumatic stress disorder: clinical summary of a five-year retrospective study, 1990–1995. Mil Med. 1997;162:616–619.CrossRefGoogle ScholarPubMed
55.Wolf, ME, Alavi, A, Mosnaim, AD. Posttraumatic stress disorder in Vietnam veterans: clinical and EEG findings; possible therapeutic effects of carbamazepine. Biol Psychiatry. 1988;23:642–644.CrossRefGoogle ScholarPubMed
56.Iancu, I, Rosen, Y, Moshe, K. Antiepileptic drugs in posttraumatic stress disorder. Clin Neuropharmacol. 2002;25:225–229.CrossRefGoogle ScholarPubMed
57.Stewart, JT, Bartucci, RJ. Posttraumatic stress disorder and partial complex seizures. Am J Psychiatry. 1986;143:113–114.Google ScholarPubMed
58.Hertzberg, MA, Butterfield, MI, Feldman, ME, et al.A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry. 1999;45:1226–1229.CrossRefGoogle ScholarPubMed
59.Bremner, JD, Mletzko, T, Welter, S, et al.Treatment of posttraumatic stress disorder with phenytoin: an open-label pilot study. J Clin Psychiatry. 2004;65:1559–1564.CrossRefGoogle Scholar
60.Berlant, J, van Kammen, DP. Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. J Clin Psychiatry. 2002;63:15–20.CrossRefGoogle ScholarPubMed
61.Van der Kolk, BA. Psychopharmacology. Psychopharmacological issues in posttraumatic stress disorder. Hosp Community Psychiatry. 1983;34:683–691.Google ScholarPubMed
62.Kitchner, I, Greenstein, R. Low dose lithium carbonate in the treatment of post traumatic stress disorder: brief communication. Mil Med. 1985;150:378–381.CrossRefGoogle ScholarPubMed
63.Forster, PL, Schoenfeld, FB, Marmar, CR, Lang, AJ. Lithium for irritability in post-traumatic stress disorder. J Trauma Stress. 1995;8:143–149.Google ScholarPubMed
64.Berigan, TR. Gabapentin in the treatment of posttraumatic stress disorder. Prim Care Companion J Clin Psychiatry. 2002;2:105.Google Scholar
65.Brannon, N, Labbate, L, Huber, M. Gabapentin treatment for posttraumatic stress disorder. Can J Psychiatry. 2000;45:84.Google ScholarPubMed
66.Malek-Ahmadi, . Gabapentin and posttraumatic stress disorder. Ann Pharmacother. 2003;37:664–666.CrossRefGoogle ScholarPubMed
67.Hamner, MB, Broderick, PS, Labbate, LS. Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy. Ann Clin Psychiatry. 2001;13:141–146.CrossRefGoogle ScholarPubMed
68.Schwartz, TL. The use of tiagabine augmentation for treatment-resistant anxiety disorders: a case series. Psychopharmacol Bull. 2002;36:53–57.Google ScholarPubMed
69.MacLeod, AD. Vigabatrin and posttraumatic stress disorder. J Clin Psychopharmacol. 1996;16:190–191.CrossRefGoogle ScholarPubMed
70.Berigan, T. Oxcarbazepine treatment of posttraumatic stress disorder. Can J Psychiatry. 2002;47:973–974.CrossRefGoogle ScholarPubMed
71.Pande, AC, Davidson, JR, Jefferson, JW, et al.Treatment of social phobia with gabapentin: a placebo-controlled stuty. J Clin Psychopharmacol. 1999;19:341–348.CrossRefGoogle Scholar
72.Blanco, C, Schneier, FR, Schmidt, A, et al.Pharmacological treatment of social anxiety disorder: a meta-analysis. Depress Anxiety. 2003;18:29–40.CrossRefGoogle ScholarPubMed
73.Simon, NM, Worthington, JJ, Doyle, AC, et al.An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry. 2004;65:1219–1222.CrossRefGoogle ScholarPubMed
74.Kinrys, G, Pollack, MH, Simon, NM, Worthington, JJ, Nardi, AE, Versiani, M. Valproic acid for the treatment of social anxiety disorder. Int Clin Psychopharmacol. 2003;18:169–172.Google ScholarPubMed
75.Jefferson, JW. Benzodiazepines and anticonvulsants for social phobia (social anxiety disorder). J Clin Psychiatry. 2001;62(suppl 1):50–53.Google ScholarPubMed
76.Pande, AC, Pollack, MH, Crockett, J, et al.Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol. 2000;20:467–471.CrossRefGoogle ScholarPubMed
77.Layton, ME, Friedman, SD, Dager, SR. Brain metabolic changes during lactate-induced panic: effects of gabapentin treatment. Depress Anxiety. 2001;14:251–254.CrossRefGoogle ScholarPubMed
78.Baetz, M, Bowen, RC. Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy. Can J Psychiatry. 1998;43:73–77.CrossRefGoogle Scholar
79.Primeau, F, Fontaine, R, Beauclair, L. Valproic acid and panic disorder. Can J Psychiatry. 1990;35:248–250.CrossRefGoogle ScholarPubMed
80.Woodman, C, Noyes, R. Panic disorder: treatment with valproate. J Clin Psychiatry. 1994;55:134–136.Google ScholarPubMed
81.Keck, PE, Taylor, VE, Tugrul, KC, McElroy, SL, Bennett, JA. Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatry. 1993;33:542–546.CrossRefGoogle ScholarPubMed
82.Brady, KT, Sonne, S, Lydiard, RB. Valproate treatment of comorbid panic disorder and affective disorders in two alcoholic patients. J Clin Psychopharmacol. 1994;14:81–82.Google ScholarPubMed
83.McElroy, SL, Keck, LPE, Lawrence, JL. Treatment of panic disorder and benzodiazepine withdrawal with valproate. J Neuropsychiatry Clin Neurosci. 1991;2:232–233.CrossRefGoogle Scholar
84.Roy-Byrne, PRWard, NG, Donnelly, PJ. Valproate in anxiety and withdrawal sydromes. J Clin Psychiatry. 1989;50(suppl 3):44–48.Google Scholar
85.Ontiveros, A, Fontaine, R. Sodium valproate and clonazepam for treatment-resistent panic disorder. J Psychiatry Neurosci. 1992;17:78–80.Google Scholar
86.Marazziti, D, Cassano, GB. Valproic acid for panic disorder associated with multiple sclerosis. Am J Psychiatry. 1996;153:6–7.Google ScholarPubMed
87.Lum, M, Fontaine, R, Elie, R, Ontiveros, A. Divalproex sodium's antipanic effect in panic disorder: a placebo-controlled study. Biol Psychiatry. 1990;27:164A–165A.Google Scholar
88.Zwanger, P, Baghai, TC, Schule, C, et al.Tiagabine improves panic and agoraphobia in panic disorder patients. J Clin Psychiatry. 2001;62:656–657.CrossRefGoogle Scholar
89.Zwanger, P, Eser, D, Padberg, F, et al.Effects of tiagabine on cholecystokinin tetrapeptide (cck-4) induced anxiety in health volunteers. Depress Anxiety. 2003;18:140–143.CrossRefGoogle Scholar
90.Zwanger, P, Baghai, TC, Schule, C, et al.Vigabatrin decreases cholecystokinin-tetrapeptide (cck-4) induced panic in healthy volunteers. Neuropsychopharmacol. 2001;25:699–703.CrossRefGoogle Scholar
91.Tondo, BL, Burrai, C, Scamonatti, L, et al.Carbamazepine in panic disorder. Am J Psychiatry. 1989;146:558–559.Google ScholarPubMed
92.Uhde, TW, Stein, MB, Post, RM. Lack of efficacy of carbamazepine in the treatment of panic disorder. Am J Psychiatry. 1988;145:1104–1109.Google ScholarPubMed
93.Kaufman, K, Gerner, R. Adjunctive oxcarbazapine in comorbid anxiety and affective disorder with hyponatremic seizure: case analysis and literature review. Epilepsy Behav. 2003;4:766–770.CrossRefGoogle Scholar
94.Windhaber, J, Maierhofer, D, Dantendorfer, K. Oxcarbazepine for panic disorder occurring after two grand mal seizures: a case report. J Clin Psychiatry. 1997;58:404–405.CrossRefGoogle ScholarPubMed
95.Rosenthal, M. Tiagabine for the treatment of generalized anxiety disorder; a randomized, open-label, clinical trial with paroxitine as a positive control. J Clin Psychiatry. 2003;64:1245–1249.CrossRefGoogle Scholar
96.Crane, D. Tiagabine for the treatment of anxiety. Depress Anxiety. 2003;18:51–52.CrossRefGoogle ScholarPubMed
97.Garcia-Campayo, J, Sanz-Carrillo, C. Gabapentin for the treatment of patients with somatization disorder. J Clin Psychiatry. 2001;62:474.CrossRefGoogle ScholarPubMed
98.Garcia-Campayo, J, Sanz-Carrillo, C. Topiramate as a treatment for pain in multisomatoform disorder patients: an open trial. Gen Hosp Psychiatry. 2002;24:417–421.CrossRefGoogle ScholarPubMed
99.McMeekin, H. Successful treatment of obsessive compulsive disorder with oxcarbazepine. J S C Med Assoc. 2002;98:316–320.Google ScholarPubMed
100.Cora-Locatelli, G, Greenberg, BD, Martin, JD, Murphy, DL. Valproate monotherapy in an SRI-intolerant OCD patient. J Clin Psychiatry. 1998;59:82.CrossRefGoogle Scholar
101.Deltito, JA. Valproate pretreatment for difficult-to-treat patient with OCD. J Clin Psychiatry. 1994;55:500.Google ScholarPubMed
102.Dannon, PN. Topiramate for the treatment of kleptomania: a case series and review of the literature. Clin Neuropharmacol. 2003;26:1–4.CrossRefGoogle ScholarPubMed
103.Burstein, A. Fluoxetine-lithium treatment for kleptomania. J Clin Psychiatry. 1992;53:28–29.Google ScholarPubMed
104.Kmetz, GF, McElroy, SL, Collins, DJ. Response of kleptomania and mixed mania to valproate. Am J Psychiatry. 1997;154:580–581.Google ScholarPubMed
105.McElroy, SL, Pope, HG, Hudson, JI, Keck, PE, White, KL. Kleptomania: a report of 20 cases. Am J Psychiatry. 1991;148:652–657.Google ScholarPubMed
106.McElroy, S, Arnold, LM, Shapira, N, et al.Topiramate in the treatment of binge-eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry. 2003;160:255–261.CrossRefGoogle ScholarPubMed
107.McElroy, SL, Shapira, NA, Arnold, LM, et al.Topiramate in the long-term treatment of binge-eating disorder associated with obesity. J Clin Psychiatry. 2004;65:1463–1469.CrossRefGoogle ScholarPubMed
108.Appolinario, JC, Fontenelle, LF, Papelbaum, M, Bueno, JR, Coutinho, W. Topiramate use in obese patients with binge eating disorder: an open study. Can J Psychiatry. 2002;47:271–273.CrossRefGoogle ScholarPubMed
109.Shapira, NA, Goldsmith, TD, McElroy, SL. Treatment of binge-eating disorder with topiramate: a clinical case series. J Clin Psychiatry. 2000;61:368–372.CrossRefGoogle ScholarPubMed
110.Appolinario, JC, Coutinho, W, Fontenelle, L. Topiramate for binge-eating disorder. Am J Psychiatry. 2001;158:967–968.CrossRefGoogle ScholarPubMed
111.Prado-Lima, SD, Bacaltchuck, J. Topiramate in treatment-resistant depression and binge-eating disorder. Bipolar Disord. 2002;4:271–273.CrossRefGoogle Scholar
112.McElroy, SL, Kotwal, R, Hudson, JI, Nelson, EB, Keck, PE. Zonisamide in the treatment of being-eating disorder: an open-label, prospective trial. J Clin Psychiatry. 2004;65:50–56.CrossRefGoogle ScholarPubMed
113.Hoopes, SP, Reimherr, FW, Hedges, DW, et al.Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures. J Clin Psyhiatry. 2003;64:1335–1341.CrossRefGoogle Scholar
114.Hedges, DW, Reimherr, FW, Hoopes, SP, et al.Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo controlled trial, part 2: improvement in psychiatric measures. J Clin Psychiatry. 2003;64:1449–1454.CrossRefGoogle Scholar
115.Levy, E, Margolese, H, Chouniard, G. Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia [letter]. J Clin Psychiatry. 2002;63:1045.CrossRefGoogle ScholarPubMed
116.Van Ameringen, M, Mancini, C, Pipe, B, Campbell, M, Oakman, J. Topiramate treatment for ssri-induced weight gain in anxiety disorders. J Clin Psychiatry. 2002;63:981–984.CrossRefGoogle ScholarPubMed
117.Felstrom, A, Blackshaw, S. Topiramate for bulimia nervosa with bipolar II disorder [Letter]. Am J Psychiatry. 2002;159:1246–1247.CrossRefGoogle ScholarPubMed
118.Colom, F, Vieta, E, Benabarre, A, Martínez-Arán, A, et al.Topiramate abuse in a bipolar patient with an eating disorder [letter]. J Clin Psychiatry. 2001;62:475–476.CrossRefGoogle Scholar
119.Citrome, L, Jaffe, A, Levine, J, Allingham, B. Use of mood stabilizers among patients with schizophrenia, 1994–2001. Psychiatr Serv. 2002;53:1212.CrossRefGoogle ScholarPubMed
120.Leucht, S, McGrath, J, Kissling, W. Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry. 2004;65:177–186.CrossRefGoogle ScholarPubMed
121.McEvoy, JP, Scheifler, PL, Frances, A. The expert consensus guideline series: treatment of schizophrenia 1999. J Clin Psychiatry. 1999;60(suppl 11):43.Google Scholar
122.Citrome, L. Schizophrenia and valproate. Psychopharmacol Bull. 2003;37(suppl 2):74–88.Google ScholarPubMed
123.Basan, A, Kissling, W, Leucht, S. Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials. Schizophr Res. 2004;70:33–37.CrossRefGoogle ScholarPubMed
124.Leucht, S, McGrath, J, White, P, Kissling, W. Carbamazepine augmentation for schizophrenia: how good is the evidence? J Clin Psychiatry. 2002;63:218–224.CrossRefGoogle ScholarPubMed
125.Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association. Am J Psychiatry. 1997;154(4 suppl):1–63.CrossRefGoogle Scholar
126.Miller, AL, Chiles, JA, Chiles, JK, Crismon, ML, Rush, AJ, Shon, SP. The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. J Clin Psychiatry. 1999;60:649–657.CrossRefGoogle ScholarPubMed
127.Leucht, S, McGrath, J, White, P, Kissling, W. Carbamazepine for schizophrenia and schizoaffective psychosis. Cochrane Database Syst Rev. 2002;(3):CD001258.CrossRefGoogle Scholar
128.Dose, M, Apelt, S, Emrich, HM. Carbamazepine as an adjunct of antipsychotic therapy. Psychiatry Res. 1987;22:303–310.CrossRefGoogle ScholarPubMed
129.Hesslinger, B, Normann, C, Langosch, JM, et al.Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. J Clin Psychopharmacol. 1998;19:310–315.CrossRefGoogle Scholar
130.Martin-Munoz, JC, Morinigo-Dominguez, AV, Mateo-Martin, I, et al.La carbamacepina: un tratamiento adjunto eficaz en las esquizofrenias. Actas Luso Esp Neurol Psiquiatr Cienc Afines. 1989;17:245–250.Google Scholar
131.Nachshoni, T, Levin, Y, Levy, A, et al.A double-blind trial of carbamazepine in negative symptom schizophrenia. Biol Psychiatry. 1994;35:22–26.CrossRefGoogle ScholarPubMed
132.Neppe, VM. Carbamazepine as adjunctive treatment in nonepileptic chronic inpatients with EEG temporal lobe abnormalities. J Clin Psychiatry. 1983;44:326–331.Google ScholarPubMed
133.Simhandl, C, Meszaros, K, Denk, E, et al.Adjunctive carbamazepine or lithium carbonate in therapy-resistant chronic schizophrenia. Can J Psychiatry. 1996;41:317.CrossRefGoogle ScholarPubMed
134.Okuma, TYamashita, I, Takahashi, R, et al.A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders. Acta Psychiatr Scand. 1989;80:250–259.CrossRefGoogle ScholarPubMed
135.Klein, E, Bental, E, Lerer, B, Belmaker, RH. Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. A controlled study. Arch Gen Psychiatry. 1984;41:165–170.CrossRefGoogle ScholarPubMed
136.Tiihonen, J, Hallikainen, T, Ryynänen, OP, et al.Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry. 2003;54:1241–1248.CrossRefGoogle ScholarPubMed
137.Kremer, I, Vass, A, Gorelik, I, et al.Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol Psychiatry. 2004;56:441–446.CrossRefGoogle ScholarPubMed
138.Hillbom, M, Tokola, B, Kuusela, V. et al.Prevention of alcohol withdrawal seizures with carbamazepine and valproic acid. Alcohol. 1989;6:223–236.CrossRefGoogle ScholarPubMed
139.Salinsky, MC, Binder, LM, Oken, BS, Storzbach, D, Aron, CR, Dodrill, CB. Effects of gabapentin and carbamazepine on the EEG and cognition in healthy volunteers. Epilepsia. 2002;43:482–490.CrossRefGoogle ScholarPubMed
140.Meador, KJ, Loring, DW, Ray, PG, et al.Differential cognitive and behavioral effects of carbamazepine and lamotrigine. Neurology. 2001;56:1177–1182.CrossRefGoogle ScholarPubMed
141.Rawson, NS, Harding, SR, Malcolm, E, Lueck, L. Hospitalizations for aplastic anemia and agranulocytosis in Saskatchewan: incidence and associations with antecedent prescription drug use. J Clin Epidemiol. 1998;51:1343–1355.CrossRefGoogle ScholarPubMed
142.Ibáñez, L, Vidal, X, Ballarín, E, Laporte, JR. Population-based drug-induced agranulocytosis. Arch Intern Med. 2005;165:869–874.CrossRefGoogle ScholarPubMed
143.Ono, S, Mihara, K, Suzuki, A, et al.Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. Psychopharmacology (Berl). 2002;162:50–54.CrossRefGoogle ScholarPubMed
144.Lucas, RA, Gilfillan, DJ, Bergstrom, RF. A pharmacokinetic interaction between carbamazepine and olanzapine: observations and possible mechanism. Eur J Clin Pharmacol. 1998;54:639–643.CrossRefGoogle ScholarPubMed
145.Sussman, NM, McLain, LW Jr.A direct hepatotoxic effect of valproic acid. JAMA. 1979;242:1173–1174.CrossRefGoogle ScholarPubMed
146.Biton, VMirza, W, Montouris, G, Vuong, A, Hammer, AE, Barrett, PS. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology. 2001;56:172–177.CrossRefGoogle ScholarPubMed
147.Corman, CL, Leung, NM, Guberman, AH. Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Can J Neurol Sci. 1997;24:240–244.Google ScholarPubMed
148.Wen, X, Wang, JS, Kivistö, KT, Neuvonen, PJ, Backman, JT. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol. 2001;52:547–553.CrossRefGoogle Scholar
149.Parsons, B, Tive, L, Huang, S. Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. Am J Geriatr Pharmacother. 2004;2:157–162.CrossRefGoogle ScholarPubMed
150.Galindo, PA, Borja, J, Gómez, E, et al.Anticonvulsant drug hypersensitivity. J Investig Allergol Clin Immunol. 2002;12:299–304.Google ScholarPubMed
151.Wong, IC, Mawer, GE, Sander, JW. Factors influencing the incidence of lamotrigine-related skin rash. Ann Pharmacother. 1999;33:1037–1042.CrossRefGoogle ScholarPubMed
152.Mackay, FJ, Wilton, LV, Pearce, GL, Freemantle, SN, Mann, RD. Safety of long-term lamotrigine in epilepsy. Epilepsia. 1997;38:881–886.CrossRefGoogle ScholarPubMed
153.Huang, CW, Tsai, JJ, Lai, ML. Lamotrigine-related skin rashes in adults. Kaohsiung J Med Sci. 2002;18:566–572.Google ScholarPubMed
154.Abou-Khalil, B, Benefit-risk assessment of levetiracetam in the treatment of partial seizures. Drug Saf. 2005;28:871–890.CrossRefGoogle ScholarPubMed
155.Ben-Menachem, E, Gilland, E. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy. Seizure. 2003;12:131–135.CrossRefGoogle ScholarPubMed
156.Cereghino, JJ, Biton, V, Abou-Khalil, B, Dreifuss, F, Gauer, LJ, Leppik, I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology. 2000;55:236–242.CrossRefGoogle ScholarPubMed
157.Betts, T, Waegmans, T, Crawford, P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure. 2000;9:80–87.CrossRefGoogle Scholar
158.Deodhar, SD, Singh, B, Pathak, CM, Sharan, P, Kulhara, P. Thyroid functions in lithium-treated psychiatric patients: a cross-sectional study. Biol Trace Elem Res. 1999;67:151–163.CrossRefGoogle ScholarPubMed
159.Marini, JL, Sheard, MH. Sustained-release lithium carbonate in double-blind study: serum lithium levels, side effects, and placebo response. J Clin Pharmacol. 1976;16:276–283.CrossRefGoogle ScholarPubMed
160.Gelenberg, AJ, Kane, JM, Keller, MB, et al.Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med. 1989;321:1489–1493.CrossRefGoogle ScholarPubMed
161.Bendz, H, Sjödin, I, Aurell, M. Renal function on and off lithium in patients treated with lithium for 15 years or more. A controlled, prospective lithium-withdrawal study. Nephrol Dial Transplant. 1996;11:457–460.CrossRefGoogle ScholarPubMed
162.Pendlebury, SC, Moses, DK, Eadie, MJ. Hyponatremia during oxcarbazepine therapy. Hum Toxicol. 1989;8:337–344.CrossRefGoogle ScholarPubMed
163.Scheinfeld, N. Impact of phenytoin therapy on the skin and skin disease. Expert Opin Drug Saf. 2004;3:655–665.CrossRefGoogle Scholar
164.Suppes, T, Chisholm, KA, Dhavale, D, et al.Tiagabine in treatment refractory bipolar disorder: a clinical case series. Bipolar Disord. 2002;4:283–289.CrossRefGoogle ScholarPubMed
165.Kalviainen, R, Brodie, MJ, Duncan, J, Chadwick, D, Edwards, D, Lyby, K. A double-blind, placebo-controlled trial of tiagabine given three-times daily as add-on therapy for refractory partial seizures. Epilepsy Res. 1998;30:31–40.CrossRefGoogle ScholarPubMed
166.Uthman, BM, Rowan, AJ, Ahmann, PA, et al.Tiagabine for complex partial seizures: a randomized, add-on, dose-response trial. Arch Neurol. 1998;55:56–62.CrossRefGoogle ScholarPubMed
167.Fritz, N, Glogau, S, Hoffmann, J, Rademacher, M, Elger, CE, Helmstaedter, C. Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy Behav. 2005;6:373–381.CrossRefGoogle ScholarPubMed
168.Thompson, PJ, Baxendale, SA, Duncan, JS, Sander, JW. Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry. 2000;69:636–641.CrossRefGoogle ScholarPubMed
169.Malmgren, K, Ben-Menachem, E, Frisén, L. Vigabatrin visual toxicity: evolution and dose dependence. Epilepsia. 2001;42:609–165.CrossRefGoogle ScholarPubMed
170.Mesa, F, Aguilar, M, Gonzalez-Moles, MA, et al.Vigabatrin-induced modification of Ki-67 expression in gingival epithelium: immunohistochemical study of a short series. J Periodontal Res. 2004;39:66–71.CrossRefGoogle ScholarPubMed
171.Lippik, IE, Willmore, LJ, Homan, RW, et al.Efficacy and safety of zonisamide: results of a multicenter study. Epilepsy Res. 1993;14:165–173.CrossRefGoogle Scholar